AR023573A1 - Formulacion farmaceutica - Google Patents

Formulacion farmaceutica

Info

Publication number
AR023573A1
AR023573A1 ARP000101880A ARP000101880A AR023573A1 AR 023573 A1 AR023573 A1 AR 023573A1 AR P000101880 A ARP000101880 A AR P000101880A AR P000101880 A ARP000101880 A AR P000101880A AR 023573 A1 AR023573 A1 AR 023573A1
Authority
AR
Argentina
Prior art keywords
weight
pharmaceutical formulation
binder
volumetric agent
volumetric
Prior art date
Application number
ARP000101880A
Other languages
English (en)
Original Assignee
Glaxo Wellcome Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Kk filed Critical Glaxo Wellcome Kk
Publication of AR023573A1 publication Critical patent/AR023573A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La formulacion farmacéutica que comprende: (a) de 1 a 50% en peso de lamivudina, o un derivado farmacéuticamente aceptable de la misma; (b) de 20 a 70% enpeso de un agente volumétrico; (c) de 20 a 50% en peso de un componente el cual es tanto un agente volumétrico como un aglutinante; (d) de 1 a 20% en peso deun aglutinante; y (e) de 1 a 10% en peso de un lubricante.
ARP000101880A 1999-04-22 2000-04-19 Formulacion farmaceutica AR023573A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9909154.8A GB9909154D0 (en) 1999-04-22 1999-04-22 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
AR023573A1 true AR023573A1 (es) 2002-09-04

Family

ID=10851982

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101880A AR023573A1 (es) 1999-04-22 2000-04-19 Formulacion farmaceutica

Country Status (9)

Country Link
EP (1) EP1180033B1 (es)
JP (1) JP2002542283A (es)
AR (1) AR023573A1 (es)
AT (1) ATE259233T1 (es)
AU (1) AU3839900A (es)
DE (1) DE60008237T2 (es)
ES (1) ES2214262T3 (es)
GB (1) GB9909154D0 (es)
WO (1) WO2000064427A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855346B2 (en) * 2001-10-05 2005-02-15 Tzu-Sheng Wu Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same
AU2004206827A1 (en) 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP2225232B1 (en) * 2007-11-29 2012-09-26 Ranbaxy Laboratories Limited Process for the preparation of substituted 1,3-oxathiolanes
WO2010137027A1 (en) 2009-05-27 2010-12-02 Hetero Research Foundation Solid oral dosage forms of lamivudine
CN102167696B (zh) * 2010-02-25 2013-09-18 南京正大天晴制药有限公司 拉米夫定草酸盐及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987000837A1 (en) * 1985-07-29 1987-02-12 Santen Pharmaceutical Co., Ltd Novel benzothiazine derivatives
GB8705083D0 (en) * 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
JPS63280025A (ja) * 1987-05-13 1988-11-17 Taisho Pharmaceut Co Ltd 吸収促進製剤の製造方法
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
JP2814296B2 (ja) * 1990-07-02 1998-10-22 大鵬薬品工業株式会社 ２―ニトロイミダゾール誘導体及びそれを含有する抗原虫剤
JP3667359B2 (ja) * 1993-12-29 2005-07-06 扶桑薬品工業株式会社 ５−フルオロウリジン誘導体の製造および医薬組成物
GB9517022D0 (en) * 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
JP3718890B2 (ja) * 1995-12-28 2005-11-24 味の素株式会社 Ｎ−ベンゾイルプロリンエステル誘導体
JPH09323932A (ja) * 1996-01-31 1997-12-16 Sankyo Co Ltd エイズ治療剤又は予防剤
AU712071B2 (en) * 1996-04-04 1999-10-28 Shionogi & Co., Ltd. Anti-HIV composition containing imidazole derivatives
US6258829B1 (en) * 1997-03-06 2001-07-10 Toa Eiyo Ltd. Cycloalka[b]pyridine-3-carbonylguanidine derivatives, process for producing the same, and drugs containing the same

Also Published As

Publication number Publication date
DE60008237D1 (de) 2004-03-18
DE60008237T2 (de) 2004-12-09
EP1180033B1 (en) 2004-02-11
ES2214262T3 (es) 2004-09-16
ATE259233T1 (de) 2004-02-15
JP2002542283A (ja) 2002-12-10
WO2000064427A2 (en) 2000-11-02
WO2000064427A3 (en) 2001-12-06
EP1180033A2 (en) 2002-02-20
GB9909154D0 (en) 1999-06-16
AU3839900A (en) 2000-11-10

Similar Documents

Publication Publication Date Title
BRPI0316532B8 (pt) composições farmacêuticas compreendendo uma droga básica ou ácida, um tensoativo, e um ácido ou base solúvel em água fisiologicamente tolerável
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
BR0309528A (pt) Comprimido com alta carga de droga
PL410219A1 (pl) Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca
AR067030A2 (es) Composiciones farmaceuticas
WO2003020217A3 (en) Novel pyrazole analogs acting on cannabinoid receptors
DE50211204D1 (de) Cannabis extrakten pharmazeutische zusammensetzung
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
ATE251133T1 (de) Neue strukturelle vitamin d derivate
BR9807383A (pt) Formulação farmacêutica que compreende amoxicilina e clavulanato
BRPI0416752B8 (pt) composição farmacêutica, uso de um ou mais compostos, e, compostos
UY29169A1 (es) Derivados de 2-amido-4 feniltiazol, su preparacion y su aplicacion en terapeutica
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
AR034343A1 (es) Combinaciones farmaceuticas
DE69715009D1 (de) Substituierte thiazolidinedione derivate, ihre herstellung und pharmazeutische zusammensetzungen, die sie enthalten
EA200200831A1 (ru) Фармацевтическая композиция, включающая пеметрексед вместе с монотиоглицерином, l-цистеином или тиогликолевой кислотой
AR032499A1 (es) Composiciones
BR0317222A (pt) Compostos de 2-aminocarbonil-quinolina como antagonistas dos receptores de difosfato de adenisina de plaquetas
ID22763A (id) Komposisi penstabil tibolon
AR023573A1 (es) Formulacion farmaceutica
BR0307320A (pt) Sistema de liberação osmótico
MA27862A1 (fr) Composition pharmaceutique
HUP0203226A2 (hu) Hatóanyagként benzamidszármazékot tartalmazó gyógyszerkészítmény
TNSN03065A1 (en) BIOPESTICIDE COMPOSITIONS
AR023781A1 (es) Formulaciones farmaceuticas